10 completed. 10 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 10 |
| Phase 2 | 1 | Completed 1 |
Follow Blindness: new trials by email Literature Review of Blindness trials Research Report on Blindness
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of the Benefit of Early Treatment With an Endothelin Inhibitor (Bosentan) in Patients With Sudden Blindness Due to Giant Cell Arteritis: CECIBO treatment - Arteritis, Giant Cell, Blindness and Low Vision | Phase 3 | Completed | Centre Hospitalier Universitaire de Nice | 8 | 2020-02-04 | 2026-06-18 |
| Aflibercept After Ranibizumab in Exudative Age-related Macular Degeneration Aflibercept - Macular Degeneration, Wet Macular Degeneration | Phase 3 | Completed | Centre Hospitalier Intercommunal Creteil | 84 | 2013-12-01 | 2026-10-27 |
| Tasimelteon for the Treatment of Non-24-hour Sleep-Wake Disorder (N24HSWD) in Blind Individuals With no Light Perception tasimelteon - Non-24-Hour Sleep-Wake Disorder | Phase 3 | Completed | Vanda Pharmaceuticals | 200 | 2011-10-01 | 2015-04-21 |
| Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder tasimelteon, Placebo - Non-24-Hour Sleep-Wake Disorder | Phase 3 | Completed | Vanda Pharmaceuticals | 20 | 2011-09-01 | 2014-10-10 |
| Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder tasimelteon, Placebo - Non-24-Hour Sleep-Wake Disorder | Phase 3 | Completed | Vanda Pharmaceuticals | 136 | 2010-08-01 | 2014-10-16 |
| Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) Ranibizumab, Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) - Macular Degeneration | Phase 3 | Completed | Bayer | 1240 | 2008-04-01 | 2014-12-12 |
| Preventing Depression in Patients With Macular Degeneration Problem Solving Treatment, Control - Depression, Macular Degeneration | Phase 3 | Completed | Thomas Jefferson University | 206 | 2001-02-01 | 2014-01-08 |
| Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity Supplemental Oxygen Management, Conventional Oxygen Management - Infant, Newborn, Infant, Low Birth Weight | Phase 2 / Phase 3 | Completed | NICHD Neonatal Research Network | 649 | 1994-02-01 | 2015-06-08 |
| Early Treatment Diabetic Retinopathy Study (ETDRS) Aspirin, Argon Laser Photocoagulation - Blindness, Diabetic Retinopathy | Phase 3 | Completed | National Eye Institute (NEI) | 1979-12-01 | 2006-09-04 | |
| Diabetic Retinopathy Study (DRS) Xenon Photocoagulation, Argon Photocoagulation, Photocoagulation - Diabetic Retinopathy, Blindness | Phase 3 | Completed | National Eye Institute (NEI) | 1972-01-01 | 2006-06-02 |
Eye Diseases (5) · Chronobiology Disorders (3) · Dyssomnias (3) · Macular Degeneration (3) · Nervous System Diseases (3) · Sleep Disorders, Circadian Rhythm (3) · Sleep Wake Disorders (3) · Vision Disorders (3) · Diabetic Retinopathy (2) · Retinal Diseases (2) · Depression (1) · Depressive Disorder (1) · Giant Cell Arteritis (1) · Premature Birth (1)
Neurologic Manifestations (10) · Pathological Conditions, Signs and Symptoms (10) · Sensation Disorders (10) · Signs and Symptoms (10) · Nervous System Diseases (7) · Vision Disorders (7) · Eye Diseases (5) · Mental Disorders (4) · Retinal Diseases (4) · Cardiovascular Diseases (3) · Occupational Diseases (3) · Vascular Diseases (3) · Diabetes Complications (2) · Diabetes Mellitus (2) · Diabetic Angiopathies (2)
tasimelteon (3) · aflibercept (2) · Aspirin (1) · Light Coagulation (1) · Ranibizumab (1) · Therapeutics (1)
Vanda Pharmaceuticals (3) · National Eye Institute (NEI) (2) · Bayer (1) · Centre Hospitalier Intercommunal Creteil (1) · Centre Hospitalier Universitaire de Nice (1) · NICHD Neonatal Research Network (1) · Thomas Jefferson University (1)
United States (5) · France (3) · Germany (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Colombia (1) · Czechia (1) · Hungary (1) · India (1) · Israel (1) · Italy (1) · Japan (1)
Alan R. Spitzer, MD (1) · Barbara J. Stoll, MD (1) · Beverly S. Brozanski, MD (1) · Charles C. Barr, MD (1) · Cynthia Cole, MD (1) · Dale L. Phelps, MD (1) · David Easa, MD (1) · David K. Stevenson, MD (1) · Edward F. Donovan, MD (1) · Eric Souied, MD (1) · Frank W. Kokomoor, MD (1) · J. David Bradford, MD (1) · James A. Lemons, MD (1)
PMID 26466871, PMID 10654946, PMID 17679633, PMID 23084240, PMID 23528439, PMID 24084500, PMID 25107900, PMID 25439429, PMID 30681643, PMID 31826853, PMID 36932356
M01RR000054 (1), M01RR000070 (1), R01MH061331 (1), U10HD021385 (1), U10HD021415 (1), U10HD027851 (1), U10HD027853 (1), U10HD027856 (1), U10HD027871 (1), U10HD027880 (1), U10HD027904 (1), U10HD040689 (1)